Nektar Therapeutics | NKTR - Operating Expenses


Nektar Therapeutics reported $49.12M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Amgen USD 11.69B 6.9B Jun/2026
Baxter International USD 2.68B 3.36B Jun/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Cipla INR 62.31B 3.04B Jun/2026
Dr.Reddys Laboratories INR 77.75B 3.17B Jun/2026
Eisai JPY 209.6B 6.14B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Exelixis USD 380.28M 20.8M Jun/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Incyte USD 973.64M 4.65B Jun/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Novartis USD 10.2B 912M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Takeda JPY 1.02T 89.68B Jun/2026
Teva Pharmaceutical Industries USD 3.92B 691M Jun/2026
Xencor USD 87.82M 5.44M Jun/2026